Latest revenue
$268.1M
as of 2026-03-31
Latest net income
$3.6M
as of 2026-03-31
Net margin
1.4%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Fair value · DCF
DCF: 10-year forecast of free cash flow, discounted at the company's WACC, with a Gordon-growth terminal at year 10. FCF is proxied by last fiscal-year net income (proper FCF needs CFO − CapEx by year, which we don't store yet). Drag the slider to test your own growth thesis — the dominant assumption in any DCF is what comes next, not what the math does with it. Beta defaults to 1.0 when not reported.
Community sentiment
Where do you think ACAD is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $3.69B
- Enterprise value
- $3.41B
- P/E (trailing)
- 9.4×
- Forward P/E
- —
- P/B
- 2.96×
- Dividend yield
- 0.0%
- 52-wk high
- $28.34
- 52-wk low
- $19.69
- Beta
- —
- Shares out
- 171.2M
5-year trend
What this company does
Item 1. Business. Company Overview We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). Our rare disease franchise is anchored by the commercial product DAYBUE, which is the first and only drug…
AI summary unavailable — showing raw filing excerpt
Generated from ACAD's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors. You should consider carefully the following information about the risks described below, together with the other information contained in this Annual Report and in our other public filings, in evaluating our business. If any of the following risks actually occurs, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. Risks Related to Our Products and Product Candidates Our prospects are highly dependent on the successful commercialization of our products. To the extent we cannot establish, maintain or…
AI summary unavailable — showing raw filing excerpt
Generated from ACAD's filing dated 2026-02-26
Profitability
Operating margin
9.8%
59.4%Net margin
36.5%
54.3%Return on equity
53.4%
72.7%Return on assets
25.0%
31.1%Leverage
Debt / equity
1.13×
82.7%Debt / assets
53.2%
38.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $268.1M | +9.7% | $3.6M | -80.8% | 1.4% |
Q4 2025 2025-12-31 | $284.0M | +9.4% | $273.6M | +90.3% | 96.3% |
Q3 2025 2025-09-30 | $278.6M | +11.3% | $71.8M | +119.1% | 25.8% |
Q2 2025 2025-06-30 | $264.6M | +9.3% | $26.7M | -20.1% | 10.1% |
Q1 2025 2025-03-31 | $244.3M | +18.7% | $19.0M | +14.7% | 7.8% |
Q4 2024 2024-12-31 | $259.6M | — | $143.7M | — | 55.4% |
Q3 2024 2024-09-30 | $250.4M | +18.3% | $32.8M | +150.3% | 13.1% |
Q2 2024 2024-06-30 | $242.0M | +46.4% | $33.4M | +2897.2% | 13.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ACAD — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$2.8M
Net activity
−$2.8M
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ACAD
Institutional value
$1.41B
Total shares held
64.4M
Distinct holders
212
-119 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 21.6M | $479.7M | +795.5K (+3.8%) | Added |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 8.7M | $193.0M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 5.7M | $126.0M | — | New |
| 4 | FIRST TRUST ADVISORS LP | 3.3M | $74.4M | +1.1M (+47.3%) | Added |
| 5 | DIMENSIONAL FUND ADVISORS LP | 3.2M | $70.2M | +234.2K (+8.0%) | Added |
| 6 | Pictet Asset Management Holding SA | 2.0M | $44.7M | +478.9K (+31.0%) | Added |
| 7 | Artisan Partners Limited Partnership | 1.3M | $29.6M | — | New |
| 8 | Nuveen, LLC | 1.0M | $23.1M | -20.5K (-1.9%) | Trimmed |
| 9 | Allspring Global Investments Holdings, LLC | 954.9K | $21.3M | +296.0K (+44.9%) | Added |
| 10 | VANGUARD FIDUCIARY TRUST CO | 875.7K | $19.5M | — | New |
| 11 | DEUTSCHE BANK AG\ | 840.4K | $18.7M | +11.8K (+1.4%) | Added |
| 12 | Invesco Ltd. | 836.5K | $18.6M | -11.5K (-1.4%) | Trimmed |
| 13 | JANE STREET GROUP, LLC | 803.3K | $17.9M | — | New |
| 14 | PRINCIPAL FINANCIAL GROUP INC | 768.2K | $17.1M | +22.9K (+3.1%) | Added |
| 15 | Bank of New York Mellon Corp | 736.6K | $16.4M | -15.4K (-2.1%) | Trimmed |
| 16 | Fisher Asset Management, LLC | 732.9K | $16.3M | +67.8K (+10.2%) | Added |
| 17 | Allianz Asset Management GmbH | 706.7K | $15.7M | +411.2K (+139.2%) | Added |
| 18 | Voya Investment Management LLC | 613.8K | $13.7M | -27.7K (-4.3%) | Trimmed |
| 19 | JUPITER ASSET MANAGEMENT LTD | 491.1K | $10.9M | -130.0K (-20.9%) | Trimmed |
| 20 | UBS Group AG | 448.5K | $10.0M | -320.8K (-41.7%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ACAD's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.